Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window

Int J Antimicrob Agents. 2017 Sep;50(3):487-490. doi: 10.1016/j.ijantimicag.2017.04.023. Epub 2017 Jun 28.

Abstract

The quantitative impact of severity of illness on pharmacodynamic thresholds is poorly defined. We used a robust cefepime outcomes cohort and previously identified pharmacodynamic breakpoints of 68% [pharmacokinetic (PK) model 1] and 74% (PK model 2) to probe interactions and relationships with modified Acute Physiology and Chronic Health Evaluation (mAPACHE) II scores. When the time that serum concentration remains above the minimum inhibitory concentration during the dosing interval (fT>MIC) was optimised, mortality was improved between mAPACHE II scores of 9-23 and 9-22 in models 1 and 2, respectively. No significant interactions were identified. These results suggest that mAPACHE II scores of 9-22 may fall within a 'Goldilocks' window in which hospital survival is improved among patients achieving goal fT>MIC thresholds.

Keywords: APACHE II score; Cefepime; Pharmacokinetic/pharmacodynamic.

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacokinetics*
  • Anti-Bacterial Agents / pharmacology*
  • Bacteremia / drug therapy*
  • Bacteremia / mortality
  • Bacteremia / pathology
  • Cefepime
  • Cephalosporins / administration & dosage
  • Cephalosporins / pharmacokinetics*
  • Cephalosporins / pharmacology*
  • Female
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Retrospective Studies
  • Serum / chemistry*
  • Severity of Illness Index*
  • Survival Analysis
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Cefepime